Densitometric measurement of bone mass is used to diagnose osteoporosis in postmenopausal women and to guide treatment decisions. BMD measurements are used to determine fracture risk and to assess changes in bone mass over time in both treated and untreated patients.³ The NOF, U.S. Preventive Services Task Force (USPSTF), and the International Society for Clinical Densitometry (ISCD) recommend that all Caucasian women aged > 65 years be offered BMD screening. BMD is expressed as a T-score which is the number of standard deviations above or below the mean for a young adult healthy population. Dual x-ray absorptiometry (DXA) of the hip is the gold standard for the diagnosis of osteoporosis using the WHO criteria. Central measurements of BMD with DXA are used to determine baseline BMD for follow-up measurements. The readily available technologies available to measure BMD include DXA, which is the most often used, ultrasonography, QCT, and radiographic absorptiometry. DXA can also be used to detect vertebral fractures in patient undergoing BMD assessment. Whenever possible, measurement of BMD at the spine and hip is recommended in all patients.